Even in Silicon Valley, skepticism looms over robots, while ‘China has certainly a lot more momentum on humanoids’

The Humanoids Summit in Mountain View attracted about 2,000 engineers and investors as generative AI has reignited funding and ambition for humanlike robots; McKinsey counts roughly 50 companies that have raised at least $100 million (about 20 in China, 15 in North America), and China’s government incentives and a 2025 ecosystem mandate have given it early momentum. Advances in visual-language models and computer vision are helping robots learn to navigate and perform tasks—illustrated by commercialsthat range from Disney’s walking Olaf to Agility Robotics’ Digit being trialed by Mercado Libre—while inexpensive platforms from Unitree are proliferating in labs. At the same time leading skeptics such as Rodney Brooks warn dexterity and general-purpose capability remain distant, Tesla’s Optimus program was notably absent, and industry groups are urging a U.S. national strategy; the takeaway for investors is significant upside if technical and supply-chain challenges are solved, but timelines and ultimate winners remain highly uncertain.

Analysis

The Humanoids Summit in Mountain View drew roughly 2,000 engineers and investors and highlighted renewed capital flows into humanoid robotics driven by generative-AI advances; McKinsey estimates about 50 companies have raised at least $100 million (≈20 in China, ≈15 in North America), and attendees emphasized visual-language models paired with computer vision as immediate technical enablers. China’s momentum is evident in its 2025 humanoid-ecosystem mandate and incentives for component production, with Chinese vendors (Unitree) prominent on expo floors and commercial showpieces such as Disney’s walking Olaf slated for Disneyland parks in Hong Kong and Paris early next year. Commercial pilots are emerging — Agility Robotics announced a Digit trial with Mercado Libre in a Texas distribution center — but panelists and figures like Rodney Brooks caution that dexterity and general-purpose workplace capability remain distant and technically challenging. The absence of a Tesla/Optimus presence and calls for a stronger U.S. national robotics strategy underscore persistent timeline and competitive risks; investors face asymmetric upside if hardware, software and supply-chain bottlenecks are solved, but should price in long development cycles and execution risk.

Key Decisions for Investors

• Consider selective exposure to companies with demonstrated commercial pilots or clear revenue pathways (for example, deployments like Disney’s Olaf and Agility’s Digit trials) rather than broad bets on speculative humanoid platforms
• Limit position sizes in early-stage humanoid hardware and hedge with software/AI or industrial-automation names because conference consensus and experts like Rodney Brooks indicate general-purpose dexterity timelines remain uncertain
• Monitor China policy and supply-chain signals (the 2025 mandate and component incentives) as leading indicators of adoption and competitive advantage, and adjust regional exposure accordingly
• Use technical and commercial milestones — repeatable field performance, improved dexterity metrics, visual-language navigation progress, and any concrete Optimus or large-customer rollouts — as triggers to reweight holdings